drugset / Trial / NCT02946554
Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The study will assess the safety of different dose regimens of HepaStem in cirrhotic Patients with ACLF or with acute decompensation at risk of developing ACLF up to Day 28 of the active study period.
Timeline
- Start
- 2016-12
- Primary completion
- 2019-07
- Completion
- 2020-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HepaStem | Cell therapy | — | — |